SciELO - Scientific Electronic Library Online

 
vol.76 issue8Tumarkin-like phenomenon as a sign of therapeutic success in benign paroxysmal positional vertigoTwenty-five years since the identification of the first SCA gene: history, clinical features and perspectives for SCA1 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Arquivos de Neuro-Psiquiatria

Print version ISSN 0004-282XOn-line version ISSN 1678-4227

Abstract

MARQUES, Vanessa Daccach et al. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq. Neuro-Psiquiatr. [online]. 2018, vol.76, n.8, pp.539-554. ISSN 0004-282X.  http://dx.doi.org/10.1590/0004-282x20180078.

The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.

Keywords : multiple sclerosis; drug therapy; consensus.

        · abstract in Portuguese     · text in English     · English ( pdf )